Tocilizumab: what can we expect from this drug in the fight against Covid-19?
Audio 06:48
By: Andréane Meslard
Rare glimmer of hope in the crisis: a drug, the immunomodulator tocilizumab, has shown its effectiveness in preventing serious forms of pneumonia from Covid-19, according to a French study not yet published, the first results of which were revealed Monday by the AP-HP. This medication, usually used in the treatment of rheumatoid arthritis, had less need for respiratory assistance and had a lower death rate during the 14 days of follow-up. RFI interviewed Professor Jacques-Eric Gottenberg, head of the rheumatology department at the CHU Strasbourg-Hautepierre.
- Coronavirus
- Health and Medicine
On the same subject
Decryption
Covid: before a treatment or a vaccine, should we focus on group immunity?
Little and big history of epidemics
The medicine that was to save Africa